secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001628280-25-036543
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback
--------------------------------------------------------------------------------

- Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.
- Board authorized up to $1 billion in share repurchases through March 31, 2026.
- Phase 3 TETON 2 study of Nebulized Tyvaso in IPF complete; data expected September 2025.
- Orenitram posted record quarterly revenue of $123.9 million, up 16% year-over-year.
- Net income of $309.5 million, or $6.86 per basic share, up 11%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/0001628280-25-036543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/uthr-20250730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-036543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer